December 17, 2007 09:29 ET

CDEX, Inc. Demonstrates Methamphetamine Scanner to Nevada Governor Gibbons and Mrs. Gibbons

TUCSON, AZ--(Marketwire - December 17, 2007) - CDEX, Inc. (OTCBB: CEXI) recently demonstrated its new ID2, Methamphetamine Scanner ("Meth Scanner") to Nevada Governor Jim Gibbons and First Lady Dawn Gibbons, who continue to lead efforts to combat methamphetamine production and use. Malcolm Philips, CEO of CDEX, explained the technology behind the Scanner and that it had been involved in several busts during its beta testing. "This technology could certainly provide much needed assistance for our law enforcement's efforts to crack down on the production, transportation, and use of methamphetamine," said Governor Jim Gibbons.

Visiting the ASHP trade show at the Sands Expo Center in Las Vegas, Mrs. Gibbons stopped by the CDEX booth to learn more about the technology and progress on deploying the Meth Scanner in the field. Mrs. Gibbons used the Scanner to identify trace quantities of methamphetamine on baby clothes. "The children are the hidden victims of methamphetamine use," said Mrs. Gibbons. "We are beginning to understand the devastating impact of meth on users and those exposed to high levels. We do not fully understand the long term impacts of extended low level exposure such as from living in a house or apartment where meth had been made or used. That may be a ticking time bomb, particularly for children." (For additional photographs of Mrs. Gibbons' visit see

The Meth Scanner identifies trace quantities of methamphetamine on all surfaces while in a continuous scan mode. The Scanner, weighing less than 1 1/2 pounds, is battery operated, handheld, non-intrusive and requires no operator interpretation of results. As to the schedule for deployment of the scanner, Philips stated, "We have received great cooperation from law enforcement agencies in Nevada, Texas, Missouri and Arizona in refining the Meth Scanner. We will put it on the market as soon as we finish the sensitivity testing in the next several weeks and it will be ready for delivery during the first quarter of the 2008."

The CDEX Methamphetamine Scanner uses the same basic technology employed in the CDEX ValiMed™ Medication Validation System, demonstrated at the ASHP trade show. ValiMed uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation. ValiMed is currently saving lives in hospitals across the nation.

About CDEX, Inc.

CDEX, Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit and or contact Malcolm Philips ( or Stuart Poteet ( at 520.745.5172 X 210 or 202.

Any statements made in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in the federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the company to raise capital to finance the development of its products, the effectiveness, profitability and marketability of those products, the ability of the company to protect its proprietary information, the establishment of an efficient corporate operating structure as the company grows and, other risks detailed from time-to-time in filings with the securities and exchange commission. There is no obligation to publicly update any forward-looking statements.

Contact Information